Introduction
Since the early 1990s, tumor necrosis factor alpha (TNFalpha) inhibitors have been successfully used in the treatment of various immune-mediated infl ammatory diseases. In April 2015, it was reported that more than 850,000 patients worldwide had been treated with these agents [ 1 ] . In 2013, Humira ® (adalimumab), Enbrel ® (etanercept), and Remicade ® (infl iximab) claimed the fi rst, fourth, and eighth place on the list of highest-grossing drugs worldwide [ 2 ] . Patent protection for most TNF-alpha inhibitors will expire until 2020. In September 2014, the fi rst infl iximab biosimilarsRemsima ® and Infl ectra ® -received marketing authorization. It is therefore safe to assume that biosimilars will play an increasingly important therapeutic role.
Target structure of TNF-alpha inhibitors (also referred to as TNF-alpha antagonists or TNF-alpha blockers) is the cytokine TNF-alpha. A central regulator of the immune system, this cytokine is involved in many endogenous processes such as infl ammation, infections, fever, and apoptosis but also in cell regeneration and proliferation [3] [4] [5] .
Apart from macrophages as the primary site of TNF-alpha synthesis, this protein is also secreted by other immune cells, including Th1 cells, Th17 cells, mast cells, and neutrophils, as well as non-immune cells such as fi broblasts, adipocytes, endothelial cells, myocytes, and neurons. Soluble TNF-alpha is released from the membrane-bound TNF precursor by proteolysis.
There are two TNF-alpha receptors. The type 1 receptor is expressed in most tissues, and is responsible for the majority of proinfl ammatory effects. By contrast, the type 2 receptor is only detectable on immune cells, endothelial cells, and neuronal cells. It is involved in cell proliferation as well as tissue homeostasis and regeneration. While membrane-bound TNF-alpha is able to activate both receptor types, the soluble form only binds to type 1.
All TNF-alpha antagonists bind to soluble and membrane-bound TNF-alpha with high affi nity and specifi city. By inhibiting the binding of TNF-alpha to its receptors, they block its biological effects. Moreover, the antibodies activate the complement system or cause lysis of TNF-alpha-expressing cells by cell-mediated cytotoxicity. Etanercept also binds to the related protein lymphotoxin-alpha (TNF-beta), which may likewise bind to both types of TNF-alpha receptors. Such combined inhibition seems to be responsible for the differences in effi cacy and safety profi les [ 6 ] .
In Germany, four TNF-alpha antibodies (infl iximab, adalimumab, certolizumab, golimumab) as well as the receptor fusion molecule etanercept are currently approved (Table 1 ) . Apart from the indications rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and uveitis, there have been reports of their successful experimental off-label use in disorders such pustular psoriasis, subcorneal pustular dermatosis, pityriasis rubra pilaris, Behçet's disease, granuloma annulare, disseminated granuloma annulare, pyoderma gangrenosum, and autoimmune bullous dermatoses [ 7, 8 ] .
Combination treatment with methotrexate is approved for all TNF-alpha inhibitors. With respect to infl iximab, such combination is even mandatory, given the risk of antibody formation against murine components of the molecule [ 9 ] and decreasing effectiveness in case of monotherapy. Compared to other TNF-alpha inhibitors, incompatibility and infusion reactions are more common on infl iximab. Although there have been reports of successful combination treatment using cyclosporine A [ 10 ] , retinoids [11] [12] [13] , or UVB [ 14 ] , such regimens are off-label (Table 1 ) .
Usually, TNF-alpha inhibitors are well tolerated. Given the amount of clinical experience gathered over the years, there is by now extensive data with respect to adverse effects. Herein, we review current knowledge with respect to cutaneous side effects of TNF-alpha inhibitors (Table 2 ) .
Cutaneous and mucosal adverse effects can be classifi ed into injection-or infusion-associated reactions, skin infections, neoplasms, immune-mediated side effects, as well as other complications.
Local injection site reactions
With approximately 30 % of all spontaneously reported adverse events, local injection-related complications represent the most common side effects. On principle, such complications can be associated with the use of any drug, and include bleeding, hematoma, erythema, pruritus, pain, edema, and urticaria [ 15, 16 ] . They occur in approximately 13 % of all injections.
In most cases, these reactions are mild, and lesions usually disappear after 3-5 days. Cooling, topical corticosteroids, and analgesics are recommended for more severe reactions. Discontinuation of anti-TNF-alpha treatment is usually not required. In case of recurrence, a decrease in severity and frequency of symptoms can frequently be observed [ 15, 16 ] (Table 3 ) .
Infusion-associated side effects
Of the aforementioned TNF-alpha inhibitors, only infl iximab is administered by infusion. Infusion reactions frequently present as hypersensitivity responses. Acute cutaneous reactions such as urticaria or erythematous rashes develop within two hours after starting the infusion; approximately 14 % of all patients are affected. Severe reactions are rare (< 1 %). The degree of humanization, the cell line, as well as additives affect the allergenic potential of biologics.
Common (1-27 %) are delayed hypersensitivity reactions -serum sickness-like reactions -that may occur 1-14 days after the injection. Here, too, cutaneous symptoms include rash, pruritus, urticaria, as well as hand and facial edema. They are particularly common on infl iximab, especially if the second dose is given more than 20 weeks after the fi rst. Remarkably, the incidence of infusion-associated hypersensitivity reactions is not affected by the prophylactic administration of corticosteroids or antihistamines, as they do not seem to be IgE-mediated [ 17, 18 ] .
Cutaneous infections
TNF-alpha plays a complex role in infl ammatory processes and immune responses. Among other things, it is required to kill intracellular microorganisms. Consequently, treatment with TNF-alpha inhibitors may potentially give rise to a multitude of infections, some of them opportunistic. The skin and the respiratory tract are among the most common sites of infections on anti-TNF-alpha therapy [ 19 ] . Infl iximab, in particular, appears to be responsible for the increased risk of infection [ 20, 21 ] .
Risk factors for infections include additional immunosuppressive therapy, malnutrition, age, and comorbidities such as rheumatoid arthritis, chronic pulmonary diseases, alcohol abuse, organic brain diseases, and diabetes [ 22, 23 ] . Infections are considered severe if they result in hospitalization, require intravenous administration of antibiotics, or are fatal. Severe bacterial skin diseases include erysipelas, cellulitis, and abscesses. They are predominantly observed during the fi rst six months of anti-TNF-alpha therapy. The incidence rate is approximately 5.0/100 patient years -most infections reported have been erysipelas [ 24, 25 ] . There are no recommendations for specifi c prophylaxis of erysipelas during treatment with TNF-alpha inhibitors. Studies on the specifi c course of bacterial infections during therapy with these agents are also lacking.
Analogous to the procedure in herpes zoster, early-stage erysipelas is no contraindication for anti-TNF-alpha therapy. However, treatment should not be initiated during an active infection.
It should be noted that the risk of skin infections on anti-TNF-alpha therapy does not seem to be higher than on systemic treatment with methotrexate, acitretin, or cyclosporine [ 26 ] .
Extrapulmonary tuberculosis and atypical mycobacterial skin infections on anti-TNF-alpha therapy are rare. Cyclosporine [ 31 ] , acitretin [ 12 ] , UVB 311 nm [ 14 ] Cyclosporine [ 31 ] , acitretin [ 11 ] , UVB 311 nm [ 11, 44 ] Abbr.: IV, intravenous; SQ, subcutaneous; INN, international nonproprietary name; TNF, tumor necrosis factor; PEG, polyethylene glycol; RA, rheumatoid arthritis; AS, ankylosing spondylitis; UC, ulcerative colitis; CD, Crohn's disease; JIA, juvenile idiopathic arthritis *from the age of 6, **from the age of 2; ***from the age of 12
With respect to the risk of pulmonary tuberculosis, the reader may be referred to the vast amount of literature available, as the present article is meant to focus on cutaneous side effects of TNF-alpha antagonists. As regards cutaneous mycobacterial infections on anti-TNF-alpha therapy, discontinuation is recommended during antibiotic treatment (3-6 months) [ 27 ] . Mucocutaneous candidiasis accounts for the majority of fungal infections [ 19 ] ; here, too, there is a lack of data.
It has been shown that the risk of reactivation of varicella zoster virus (VZV) infection is only increased on infl iximab yet not on adalimumab and etanercept [ 28 ] . The Centers for Disease Control and Prevention in the USA have recommended that VZV vaccination be offered to all patients above the age of 60 who are to be treated with TNF-alpha inhibitors, irrespective of their exposure status. Since this is a live attenuated vaccine, it should be given prior to starting anti-TNF treatment [ 25 ] . In particular prior to infl iximab therapy, such vaccination should be considered [ 29 ] . While a previous VZV infection is no contraindication for TNF-alpha inhibitor therapy, treatment should not be initiated during active disease. In case of VZV infection on TNF-alpha inhibitors, treatment should -if possible -be interrupted until skin lesions have completely healed; moreover, antiviral therapy should be initiated [ 16, 22 ] (Table 3 ) .
Neoplasms
Metaanalyses of randomized controlled trials of adalimumab, etanercept, and infl iximab have shown the relative risk of nonmelanoma skin cancer (NMSC) on anti-TNF-alpha therapy to be 2.02; however, it is not increased for other types of cutaneous neoplasms [ 30 ] . The majority of NMSC lesions are basal cell carcinomas, less frequently squamous cell carcinomas. Accordingly, the various summaries of product characteristics call for NMSC screening prior to and during treatment. However, it should be borne in mind that most data comes from patients with rheumatoid arthritis who are generally at an increased risk of cancer. Previous or concomitant therapies with psoralen and UVA (PUVA), cyclosporine, methotrexate, or thiopurines may increase the incidence of neoplasms. Therefore, it is impossible to reliably estimate the sole effects of TNF-alpha inhibition in this regard [ 16 ] . Except for methotrexate, combination regimens are off-label and also rare. There is currently no recommendation for any particular TNF-alpha inhibitor in the context of such combination therapies [11] [12] [13] [14] 31 ] .
Compared to the general population, mycosis fungoides and Sézary syndrome have been more frequently reported when combining TNF-alpha inhibitors with thiopurines such as azathioprine. However, mortality rates associated with these two disorders are not increased in patients on anti-TNF-alpha therapy. Tumor regression following discontinuation of anti-TNF-alpha therapy has been described [ 15, 32 ] (Table 3 ) .
Immune-mediated reactions and other complications
TNF-alpha inhibitors are successfully used for the treatment of infl ammatory, noninfectious skin reactions. In case of new onset or exacerbation of the following dermatoses during anti-TNF-alpha therapy, such reactions are referred to as "paradoxical": plaque psoriasis, palmoplantar pustular psoriasis, generalized pustular psoriasis (von Zumbusch type), hidradenitis suppurativa, lupus erythematosus (cutaneous type, drug-induced), vasculitis, bullous dermatoses, granuloma annulare, lichen planus, alopecia areata, vitiligo, and sarcoidosis [ 8 ] . While 80 % of these paradoxical Table 2 Important skin reactions during treatment with TNF-alpha inhibitors as listed in the various summaries of product characteristics [ 38, 39, [45] [46] [47] .
Mechanism Examples
Local injection site reaction Bleeding, hematoma, erythema, pruritus, pain, swelling Skin infections Erysipelas, abscess, herpes zoster, herpes simplex, tinea, candidiasis
Immune-mediated and toxic complications Psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, dermatomyositis, cutaneous lupus erythematosus, lupus-like syndrome, cutaneous vasculitis (including purpura), granuloma annulare, sarcoidosis, alopecia areata, vitiligo, lichen planus, bullous dermatoses, allergic reactions (hypersensitivity, urticaria, angioedema), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis Neoplasms Squamous cell carcinoma, basal cell carcinoma, mycosis fungoides/Sézary syndrome Other skin reactions Onychorrhexis, hyperhidrosis, pruritus Table 3 Management of select skin reactions during anti-TNF-alpha treatment [ 17 ] .
Skin reaction Management Discontinuation of TNF-alpha inhibition

Local injection site reaction
Cooling, topical corticosteroids, pain management Prevention: change of injection sites.
Generally not required. reactions represent a new-onset disease, 20 % of cases refl ect an exacerbation of a preexisting disease [ 33, 34 ] . Potentially life-threatening disorders such as Stevens-Johnson syndrome have also been observed [ 34, 35 ] .
The most common immune-mediated paradoxical side effect of TNF-alpha inhibitors -the exacerbation or new onset of psoriatic skin lesions -disproportionately frequently involves palmoplantar pustular psoriasis [ 36 ] . Plaques are characterized by the dominance of Th17 and Th1 cells. The extent of the infi ltrates correlates with the number of IL-17A-producing T cells. In mild cases, topical treatment with corticosteroids, UVB therapy, and PUVA are suffi cient. Only few patients require systemic treatment and discontinuation of TNF-alpha inhibition or switching to a different biologic [ 16, 37 ] . Switching to an anti-IL-12/IL-23 agent (for example ustekinumab) is often highly effective [ 37 ] (Table 3 ) .
Other rare nonimmune-mediated side effects include onychorrhexis and hyperhidrosis [38] [39] [40] . Experience with biosimilars is limited. Based on preliminary observational studies, side effect profi les (etanercept: TuNEX, HD203; infl iximab: CT-P13, SB2, BOW015, SB4; and adalimumab: ZRC-3197) are similar to those of the brand name drugs, and show comparable effi cacy and tolerability. Here, too, mild to moderate injection site reactions and allergic reactions are common cutaneous side effects [41] [42] [43] .
Conclusions
Cutaneous adverse effects rank among the most common complications in patients treated with TNF-alpha inhibitors. In most cases, such events are mild, and do not require treatment discontinuation. However, severe skin reactions such as severe infections, neoplasms, and immune-mediated reactions may necessitate discontinuation or switching to another biologic (Table 3 ). The scientifi c literature provides no information on further specifi c therapeutic consequences for the treatment of bacterial infections; here, available data is insuffi cient.
If cutaneous adverse events occur during treatment with TNF-alpha inhibitors -no matter whether they are administered based on a dermatological or non-dermatological indication -dermatologists are key partners in the interdisciplinary management, and their expertise should be utilized.
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